News

FDA approves Ultragenyx's FAYUVI, first-ever treatment for Sanfilippo syndrome type A

What's the news? The US Food and Drug Administration (FDA) granted standard full approval on 17 September 2026 to Ultragenyx Pharmaceutical's FAYUVI (rebisufligene etisparvovec-hopf, also known as UX111). It is the first FDA-approved treatment for Sanfilippo syndrome type A (mucopolysaccharidosis type IIIA), an ultra-rare inherited disease in which children progressively lose brain function and typically die in their teens.

Why it matters: FAYUVI is a gene therapy: a harmless adeno-associated virus (AAV) is engineered to carry a working copy of the faulty gene into the patient's cells, potentially slowing or stopping the neurological decline. The approval covers the neurological symptoms of the disease in children who still have preserved neurodevelopmental function. It is Ultragenyx's second approved gene therapy and is manufactured entirely in the United States — at the company's facility in Bedford, Massachusetts, and at Andelyn Biosciences in Columbus, Ohio. Reuters reported the company set a list price of $3.95 million for the therapy.

Read more: StockTitan, 17 September 2026

More top stories